Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug Lawsuit claims delays will prevent desperate patients from accessing the therapy if approved

https://www.statnews.com/pharmalot/2026/05/08/capricor-accuses-nippon-slow-walking-plans-for-duchenne-drug/ By Ed SilvermanMay 8, 2026 Pharmalot Columnist, Senior Writer ed.silverman@statnews.com Capricor Therapeutics accused Nippon Shinyaku and its U.S. subsidiary of failing to follow through on marketing plans for a Duchenne muscular dystrophy treatment, and refusing to fix a pricing glitch that was belatedly discovered in their exclusive distribution agreement.